One of the most critical parts of drug discovery and development is identifying the structure of the drug substance and drug product. For crystalline materials and biologicals it is routine to determine the arrangement of covalent bonds in the drug substance and drug product and the structure of the solid forms of the drug substance. Read more
Non-crystalline phases such as amorphous states can lead to increased solubility for drugs. However, amorphous materials are notoriously unstable and tend to crystallize over time. As such, many amorphous materials are created in a dispersion with a polymer to increase their physical stability. X-ray powder diffraction patterns of amorphous materials are broad and not useful Read more
Current approaches to accelerated drug development typically involve parallel track activities utilizing sophisticated project management capabilities. Improved Pharma has developed a strategy that continues to utilize these project management tools but in addition utilizes predictive tools based on structure analysis of formulations and anticipation of major instabilities of formulations by assessing formulation risk. Orphan drugs Read more
Award honorees have made significant contributions to pharmaceutical sciences that promote public health ARLINGTON, VA (SEPTEMBER 21, 2018) The American Association of Pharmaceutical Scientists (AAPS) is proud to announce the winners of four of its global leadership awards: Pharmaceutical Global Health, Emerging Leader, AAPS Foundation Graduate Fellowships, and Student Chapter of the Year. Recognizing leaders Read more
Dr. Stephen Byrn and his co-authors have published an updated and thorough textbook focused on solid-state properties of pharmaceutical materials. Building off of his first textbook, Solid-State Chemistry of Drugs, this newest publication brings together solid-state chemistry, key analytical techniques, critical physical attributes, and a strategic approach for selecting and producing the correct form. With Read more
Improved Pharma, LLC is also proud to announce a collaboration with Excelsus Structural Solutions (ESS, Switzerland) to provide services related to Synchrotron X-ray diffraction for both amorphous and crystalline materials. The combination of Prof. Byrn's expertise in structural characterization of amorphous pharmaceuticals via total scattering, spectroscopic and thermal techniques, with recent advances by ESS Read more
Professor Simon Billinge of Columbia University and Improved Pharma have established a collaboration agreement to provide Synchrotron services to the pharmaceutical industry and pharmaceutical developers in a seamless manner. This collaboration will greatly simplify business linkages to Professor Billinge’s program. In many cases Improved Pharma will collect data at Professor Billinge’s direction and he will Read more
Dr. Pamela A. (Martoglio) Smith has joined Improved Pharma as COO. Dr. Smith was most recently Vice President of Analytical Services for AMRI, where she was responsible for 300 employees at four global sites. One of those sites included SSCI, the cGMP contract research organization founded by Dr. Steve Byrn and Sally Byrn. She has Read more
